Results of the most comprehensive analysis to date of the impact of gender differences in lung cancer incidence in the United States indicate that lung cancer rates among men are on the decline, while the rate in women remains steady.
A new study in the March issue of
Results of the most comprehensive analysis to date of the impact of gender differences in lung cancer incidence in the United States indicate that lung cancer rates among men are on the decline, while the rate in women remains steady.
, the peer-reviewed journal of the
lung cancer, shows that, in addition to the unequal incidence of
lung cancer in men and women, there are other gender-linked differences, including subtype of lung
cancer and survival rate.
"Traditionally, lung cancer has been viewed as a disease of older male smokers, but that is not necessarily the case," said the study's author, Gregory P. Kalemkerian, MD, University of Michigan Medical Center, Ann Arbor, MI. "This data supports the fact that lung cancer is becoming a bigger problem in women every year. If these current trends continue, in 10 to 15 years, the incidence of lung cancer will be identical for women and men."
Researchers from the lung cancer and cancer analyzed data of 228,572 patients (81,843 women and 146,729 men) with lung cancer who were registered in the national, population-based Surveillance, Epidemiology, and End Results (SEER) database between 1974 and 1999. Researchers found that the incidence of lung cancer in men reached a peak in 1984, when 72.5 of every 100,000 men had the disease, then declined to 47 per 100,000 men in 1991. In sharp contrast, the incidence of lung cancer in women continued to rise to a peak with 33.1 per 100,000 women in 1991, and then remained relatively stable at 30.2 to 32.3 per 100,000 women from 1992 to 1999. These variations have resulted in a male/female incidence ratio change from 3.56:1 in 1975 to 1.5:1 in 1999. For both men and women, the median age of diagnosis was 66 years. Women made up 40.9% of patients under the age of 50 but only 35.4% of patients over the age of 50.